Medsolve Dynamics

Short, operator-level strategy for radiation oncology and cancer program leaders navigating margin pressure, capital decisions, and AI reality. No fluff. No pitch. Just what the vendor isn't telling you.

Medsolve Dynamics is a business podcast hosted by Unknown Host, with 72 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts Medsolve Dynamics, a business show with 72 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Medsolve Dynamics

  The Escalator Nobody Argues About

  Aug 17, 20261 min

  Every service agreement has one clause that grows on its own, and it is almost never the clause that gets negotiated. Yoel Bakas on what a five percent annual step actually costs across a five year term, why the arithmetic surprises people who have signed dozens of these, and where the money goes when nobody owns the renewal date. Recorded at the AMAC Summer Seminar 2026. From Medsolve Dynamics. medsolvedynamics.com | team@medsolvedynamics.com

  ListenShow Notes
• 

  Medsolve Dynamics

  Sixteen Months of Ordinary Course

  Aug 12, 20261 min

  The radiopharmaceutical supply chain consolidated on paper on August 3, 2026, when Curium and Lantheus signed a definitive merger agreement. Yoel Bakas on why the period between signing and closing — an outside date of May 2, 2027, with extensions capped at November 30 — is the only window in which a supplier has a structural reason to give you terms, and what to ask for while it is open. From Medsolve Dynamics. team@medsolvedynamics.com | medsolvedynamics.com

  ListenShow Notes
• 

  Medsolve Dynamics

  The Half-Million-Dollar Anchor

  Aug 10, 20262 min

  A radiation oncology capital price that has not moved in twenty years. Onboard imaging, arc delivery, the next iteration of arc delivery, a couch upgrade — all half a million dollars. The same couch is $250,000 on the older platform and half a million on the new one. Yoel Bakas spent two decades on the vendor side handing programs that number, and explains what it actually is: an anchor set to shape your budget before you have built the case for the purchase. Covered: how anchor pricing differs from cost-based pricing, why the number is self-reinforcing, what belongs in a one-page business case for a capital add-on, and how to arrive at a vendor meeting with your own number instead of theirs. Medsolve Dynamics — capital strategy, financial strategy, revenue and margin growth, and AI reality checks for oncology programs. team@medsolvedynamics.com | medsolvedynamics.com

  ListenShow Notes
• 

  Medsolve Dynamics

  Price the AI, Not the Demo: Two Questions Before You Buy Theranostics Response-Monitoring Software

  Jul 13, 20261 min

  Yoel Bakas, computer science and an MBA in artificial intelligence, twenty years configuring and pricing this class of technology from the vendor side, on the two questions radiation oncology and theranostics programs should ask before buying AI response-monitoring or workflow software: does it have a billing pathway (or is it an operating expense with no code to bill against), and who owns the output when the software touches a clinical decision. For hospital and freestanding radiation oncology administrators, CFOs, and theranostics program leads evaluating AI, software renewals, and capital vs operating spend. medsolvedynamics.com | team@medsolvedynamics.com

  ListenShow Notes
• 

  Medsolve Dynamics

  Running the Theranostics Plan at Drug Margin Zero

  Jul 8, 20262 min

  The CY 2027 OPPS proposed rule puts the 340B drug spread underneath hospital theranostics programs on the table. Two drugs carry the category, Pluvicto and Lutathera, and for many programs the spread is what made the line lucrative. This episode covers the discipline: nobody tears up a program on a proposed rule, and nobody signs capital before checking whether the plan still works if the rule sticks. Three drug prices to test before the FY28 budget locks, and what a theranostics business plan has to stand on when the drug margin goes to zero. medsolvedynamics.com | team@medsolvedynamics.com

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.